TuHURA Biosciences, Inc.
NASDAQ:HURABiotechnology
Healthcare
$1.36 +6.37%
+$0.14 today
- Market cap
- $89.43M
- Beta
- 0.01
- P/E (TTM)
- -4.6
- EPS (TTM)
- -$0.52
52W Low $0.41High $3.90
Volume 0.20M
Average 0.85M
Cash Flow
Check whether earnings turn into cash.
Operating Cash Flow
-$27.63M
FY 2025 · Annual
Investing Cash Flow
-$1.34M
FY 2025 · Annual
Financing Cash Flow
$19.93M
FY 2025 · Annual
-33.1% YoYCash Flow Statement
USD
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (7.02M) | (9.37M) | (29.32M) | (21.68M) | (30.05M) |
| Depreciation & Amortization | 380.69K | 373.09K | 177.38K | 116.71K | 71.27K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 654.53K | 218.28K | 478.89K | 1.96M | 6.42M |
| Change in Working Capital | (55K) | 1.56M | 486.92K | 3.29M | (3.15M) |
| Accounts Receivables | 0 | 0 | 0 | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 0 | 0 | 0 | 0 | 0 |
| Other Working Capital | (55K) | 1.56M | 486.92K | 3.29M | (3.15M) |
| Other Non-Cash Items | (527.06K) | (294.07K) | 21M | 1.59M | (924.51K) |
| Operating Cash Flow | (6.56M) | (7.51M) | (11.95M) | (14.73M) | (27.63M) |
| Capital Expenditures | (3.28K) | (232K) | (79.22K) | (57.91K) | (76.08K) |
| Acquisitions (Net) | 0 | 0 | (1.22M) | (5.99M) | (1.26M) |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (3.28K) | (36.28K) | (1.3M) | (6.05M) | (1.34M) |
| Debt Repayment | 294.07K | (350K) | 2.69M | 28.57M | 616.98K |
| Common Stock Issued | 5.6M | 1.9M | 10.58M | 5M | 21.92M |
| Common Stock Repurchased | 0 | 0 | (24.75K) | 0 | 0 |
| Dividends Paid | (8K) | (8K) | (6K) | 0 | (8.36K) |
| Other Financing Activities | 8K | 0 | 0 | (3.8M) | (2.61M) |
| Financing Cash Flow | 7.04M | 16.25M | 2.66M | 29.77M | 19.93M |
| Effect of Forex Changes | 0 | 0 | 0 | 0 | 0 |
| Net Change in Cash | 477.91K | 8.71M | (10.59M) | 8.99M | (9.04M) |
| Free Cash Flow | (6.57M) | (7.54M) | (12.03M) | (14.79M) | (27.71M) |
Free Cash Flow
Net Income to FCF bridge
FY2025
= Net Income-$30.1M
+ D&A$71.3K
+ Stock-Based Comp$6.4M
+ Deferred Tax$0
- Working Capital-$3.1M
- Other Non-Cash-$924.5K
= Operating Cash Flow-$27.6M
- Capex-$76.1K
= Free Cash Flow-$27.7M
Analysis
FY2025 free cash flow is -$27.7M. FCF conversion is 92.2% of net income. Operating cash flow was -$27.6M, with capex of -$76.1K. The largest bridge item is Stock-Based Comp at $6.4M.
Recent Filings
Recent regulatory filings
| Filing | Description | Date | |
|---|---|---|---|
| 8-K | Current report | Nov 13, 2026 | |
| 10-Q | Quarterly report | Nov 13, 2026 | |
| 8-K | Current report | Nov 6, 2026 | |
| 8-K | Current report | Oct 16, 2026 | |
| 8-K | Current report | Sep 24, 2026 |
Does HURA generate free cash flow?
TuHURA Biosciences, Inc. (HURA) generated -$27.71M of free cash flow in fiscal 2025.
How much operating cash flow does HURA produce?
Operating cash flow was -$27.63M, before capital expenditures of $76,083.00.
Continue the stock analysis
Jump to another research area for this company.